Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial

BALLERUP, Denmark, October 11, 2023--Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial

Related Keywords

Denmark ,United States ,United Kingdom ,Germany ,Vancouver ,British Columbia ,Canada ,New York ,Ballerup ,Hovedstaden ,University Hospital ,American ,Kreesten Meldgaard Madsen ,Jes Frederiksen ,Stephan Weidinger ,Henrik Heskjaer ,Department Of Dermatology ,Global Development ,Global External Communications ,Stephan Weidinger Department Of Dermatology ,University Of Southampton ,Global Corporate Affairs ,National Library Of Medicine ,University Hospital Schleswig Holstein ,Michael Ardern Jones Department Of Dermatology ,American Academy Of Dermatology ,Icahn School Of Medicine At Mount Sinai ,Dermedge Research Center ,American Academy Of Dermatology Annual Meeting ,Emma Guttman Yassky Department Of Dermatology ,American Academy ,Annual Meeting ,First Subject Treatment ,Chief Development Officer ,Emma Guttman Yassky ,Icahn School ,Mount Sinai ,Michael Ardern Jones ,Southampton General Hospital ,Chih Ho Hong ,Greater Vancouver ,Dermatology Annual Meeting ,New Orleans ,Different Doses ,Adults With Moderate To Severe Atopic ,Allergy Clin ,Leo Pharma ,Atopic Dermatitis ,Steering Committee ,Eceptor Subunit ,